← Back to Search

Behavioral Processes for Smoking and Vaping Dual Use (DUET Trial)

N/A
Recruiting
Research Sponsored by Brown University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 21 to 34 (inclusive)
Be between 18 and 65 years old
Must not have
Urine-screened or past month illicit substance use other than marijuana (amphetamine, cocaine, methamphetamine, opioids, benzodiazepines
Pregnant (due to toxicity of tobacco products)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up laboratory session 1, approximately 1 week after baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial will investigate the behavioral processes that make cigarettes and e-cigarettes appealing to young adults, in order to help identify interventions for smoking and vaping.

Who is the study for?
This trial is for young adults aged 21-34 who regularly use both electronic nicotine delivery systems (ENDS) and combustible cigarettes. Participants must have used both products on at least 6 of the past 7 days, own a smartphone, speak English at an 8th grade level or higher, and not be planning to quit smoking/vaping or travel in the next month. Pregnant individuals or those with current alcohol dependence, illicit substance use other than marijuana, psychosis, mania, or suicidal ideation are excluded.
What is being tested?
The study examines how cues related to vaping and smoking affect cravings and attention in dual users of ENDS and combustible cigarettes. It involves lab sessions where participants react to cues from these products and complete tasks assessing their attentional bias towards them. Additionally, they will use a smartphone app for real-time monitoring over a month to track craving levels and product usage in daily life.
What are the potential side effects?
There are no direct side effects from participating as this is a behavioral study involving assessments rather than medical interventions. However, there may be discomfort from craving elicited by exposure to smoking/vaping cues during the tasks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 21 and 34 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not used illegal drugs other than marijuana in the past month.
Select...
I am not pregnant.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~laboratory session 1, approximately 1 weeks after baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and laboratory session 1, approximately 1 weeks after baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Attentional bias (objective) (Session 1)
Attentional bias (objective) (Session 2)
Change in acute craving for bottled water before and after cue exposure (Session 1)
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Study ProtocolExperimental Treatment3 Interventions
All participants will receive all laboratory protocol components in a within-person randomized order across two sequential laboratory sessions.

Find a Location

Who is running the clinical trial?

Brown UniversityLead Sponsor
466 Previous Clinical Trials
698,901 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,597 Previous Clinical Trials
3,328,843 Total Patients Enrolled
10 Trials studying Vaping
5,072 Patients Enrolled for Vaping

Media Library

Choice Task Clinical Trial Eligibility Overview. Trial Name: NCT05280535 — N/A
Vaping Research Study Groups: Study Protocol
Vaping Clinical Trial 2023: Choice Task Highlights & Side Effects. Trial Name: NCT05280535 — N/A
Choice Task 2023 Treatment Timeline for Medical Study. Trial Name: NCT05280535 — N/A
Vaping Patient Testimony for trial: Trial Name: NCT05280535 — N/A
~0 spots leftby Dec 2024